A failed batch carries the cost of everything that happened before it failed. API, excipients, processing time, analytical work and production capacity are already committed. For a development programme, the consequences can also include delayed clinical supply or another round of scale-up work.
Process analytical technology, or PAT, creates an opportunity to identify relevant changes while the process is running. Tools such as Phyllon’s OSeeT illustrate how better visibility into coating quality can support more reliable manufacturing. The investment case depends on connecting that information to decisions that prevent losses.
By Philippe Tschopp
Understanding what happens during coating
For coated tablets and pellets, an acceptable average weight gain does not describe the complete coating distribution. Differences between units, and across the surface of an individual unit, can remain hidden.
OSeeT uses optical coherence tomography, or OCT, to obtain cross-sectional information about pharmaceutical layers. For suitable transparent or semi-transparent coatings, it provides direct measurements (without calibration or multivariate data analisys), and indirect measurements in case of non-transparent materials of thickness and information on variability, homogeneity and surface roughness. Phyllon offers configurations for at-line assessment and in-line monitoring, including pan and fluid-bed coating applications.[1]
Published research has demonstrated in-line OCT measurement of coating growth on moving tablets. Markl and colleagues showed that the technique could characterise variation within individual tablets and between tablets, with results checked against offline measurements.[2]
A later feasibility study assessed commercial coated tablets in a miniature rotating drum. Thickness, homogeneity and roughness could be evaluated for the formulations investigated. This supports the analytical approach, although it does not establish universal suitability for every formulation or production environment.[3]
The practical benefit is a clearer view of the product being made while there is still an opportunity to act.
Better yield starts with defining the loss
PAT can support higher yield, but “yield” needs a clear definition.
Material yield describes how much input material becomes acceptable product. First-pass yield describes how much production meets requirements without additional processing or corrective work. Released output adds the commercial question of how much compliant product becomes available for supply.
These measures can improve through different mechanisms. Earlier detection of a coating problem may prevent a batch from being rejected. A better endpoint may reduce unnecessary spraying. More consistent processing may reduce the need for approved additional processing.
These are potential outcomes of a functioning control strategy. An instrument by itself does not deliver them. FDA’s PAT framework explicitly identifies opportunities to reduce cycle times and prevent rejects, scrap and reprocessing, while recognising that benefits depend on the product and process.[4]
For an OSeeT application, the business case should therefore begin with a specific loss: coating-related rejection, excessive endpoint margins, repeated development runs or lengthy troubleshooting.
Earlier intervention can reduce failed batches
Consider a coating process in which the mean thickness increases as expected, but the distribution becomes wider. A satisfactory average may conceal a growing population of insufficiently coated units.
If a validated monitoring approach detects that change early, operators may be able to investigate and adjust the process within established operating limits. The response might involve checking spray delivery, mixing or other process conditions. The measurement indicates a change; process knowledge is needed to identify its cause.
This is the pathway by which PAT can help reduce out-of-specification production:
Relevant measurement → early detection → justified action → verified product quality.
The distinction between a process alert and a formal out-of-specification result matters. An early warning is not automatically an OOS result. Conversely, an OOS result requires an appropriate investigation and cannot simply be set aside because other process data look acceptable.[5]
Better monitoring may initially reveal more deviations because previously unseen variability becomes visible. Success should be judged by fewer preventable failures and more consistent quality over time.
The sources reviewed support OCT measurement capabilities and process-development applications. They do not establish a general, independently verified percentage reduction in commercial failed batches attributable to OSeeT.
Connecting coating structure with drug release
For functional coatings, the development objective extends beyond applying a specified amount of polymer. The film must deliver the intended product performance.
Sacher and colleagues developed models linking in-line OCT coating-thickness measurements to dissolution profiles for tablet pan coating and pellet fluid-bed coating. Their 2024 study demonstrates the feasibility of predicting dissolution during coating within the systems investigated.[6]
This is particularly relevant to formulation development, but can also be applied during industrial production, to have under control a broader amount of products. Measurements can help teams investigate how coating structure relates to release behaviour and whether a process change produces a meaningful product change.
However, coating thickness is not always a universal substitute for dissolution testing. A relationship established for one formulation needs evidence before it is applied to another. Changes in film composition or formation may affect performance in ways that thickness alone cannot explain.
This is where excipient understanding and PAT meet: a useful measurement must be interpreted in the context of the formulation.
Addressing the development and manufacturing pain points
The following are practical opportunities to test in a development programme or site-specific pilot, rather than guaranteed outcomes.

These opportunities fit the quality by design approach described in ICH Q8(R2): use development knowledge to establish appropriate manufacturing controls and consistently deliver the intended product performance.[7]
For a CDMO and its customer, shared process evidence can also make technical discussions more productive. Differences between development and manufacturing runs become easier to describe, investigate and resolve.
Comparing the investment with the cost of poor quality
The relevant comparison is the total implemented cost against the losses the system can realistically prevent.
The investment includes the instrument, probes, installation, equipment interfaces, qualification, application development, validation, training and any production downtime needed for implementation.
Recurring costs may include service, software, verification, data review, model maintenance where applicable, and support for additional products.
The following example is hypothetical. It is neither an OSeeT quotation nor a forecast of its performance.

The assumed improvement is two percentage points, equivalent to a 67% relative reduction in the specified rejection rate. That is a substantial improvement and would require convincing evidence.
The calculation is straightforward:
Annual net benefit = avoided losses + other non-overlapping savings − recurring PAT costs.
Simple payback = initial implemented investment ÷ annual net benefit.
If only one rejected batch were avoided annually, while the other assumptions remained unchanged, net benefit would fall to €60,000 and payback would extend to approximately 4.2 years. If no other savings were realised either, payback would extend to 12.5 years.
This sensitivity matters. The strongest investment case starts with losses that are frequent enough, expensive enough and genuinely addressable by the measurement.
Avoid double counting. The same saved batch cannot be counted once as avoided scrap and again as additional output without reconciling the economic basis. Freed equipment hours have financial value only when they reduce expenditure or enable output that can actually be sold.
Likewise, reducing inventory can release working capital, but that release is different from recurring annual profit. A full investment appraisal should include implementation time, the ramp-up of benefits and discounted cash flows.
Establishing a credible application
OSeeT suitability should be demonstrated using the actual product and expected process conditions.
Phyllon distinguishes direct measurement of transparent or semi-transparent layers from indirect approaches for strongly scattering materials. Its website describes some indirect applications as beta or development software.[1] Their maturity and validation requirements should be confirmed for the intended use.
Direct OCT thickness measurement can avoid a product-specific chemometric calibration model, but conversion from optical to physical thickness depends on refractive-index information.[2] This does not remove the need for qualification, verification and a suitable analytical procedure.
A practical implementation should establish:
- Measurement suitability: Can the relevant layers and changes be measured reliably?
- Representative sampling: Do the observations describe the batch sufficiently for the intended decision?
- Actionable limits: What requires intervention, and which responses are justified?
- Reliable operation: How are poor signals, fouling, downtime and missing data handled?
- Demonstrated economics: Do matched production data show fewer attributable losses after implementation?
Start with the process and failure mechanism where these questions can be answered clearly.
Building value before changing release testing
PAT can support development, troubleshooting and process control without immediately replacing established release tests.
Real-time release testing is a further step. EMA guidance describes the requirements for using process information and controls to demonstrate compliance with approved specifications. Installing a sensor does not, by itself, authorise a change to the release strategy.[8]
For many manufacturers, the initial value may come from better decisions during production. Reduced testing or faster release should enter the financial model only when the necessary scientific and regulatory basis exists.
For developers, the opportunity is to learn more from each batch and carry that knowledge into scale-up. For manufacturers, it is to prevent avoidable losses and make compliant output more predictable. For patients, the intended benefit is reliable product quality and supply.
The strongest PAT investment case links a measurable production problem to a measurement that enables a better decision. OSeeT offers a concrete example for suitable coating applications. The return depends on how effectively that information is used.
By Philippe Tschopp
Philippe Tschopp writes about pharmaceutical excipients, formulation and oral drug delivery, with a focus on excipient functionality, practical formulation considerations and lesser-known material properties.
Sources:
- Phyllon GmbH. OSeeT: application range, systems, and direct versus indirect measurements. Manufacturer information, accessed 28 October 2026. https://www.phyllon.at/oseet/
- Markl D, et al. In-Line Monitoring of a Pharmaceutical Pan Coating Process by Optical Coherence Tomography. Journal of Pharmaceutical Sciences. 2015;104(8):2531–2540. https://doi.org/10.1002/jps.24531
- Sacher S, Peter A, Khinast JG. Feasibility of In-line monitoring of critical coating quality attributes via OCT: Thickness, variability, film homogeneity and roughness. International Journal of Pharmaceutics: X. 2021;3:100067. Published online 17 December 2020. https://doi.org/10.1016/j.ijpx.2020.100067
- US FDA. PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Guidance for Industry. 2004. https://www.fda.gov/media/71012/download
- US FDA. Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production. Guidance for Industry, Level 2 revision. May 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision
- Sacher S, et al. Real-time prediction of dissolution profiles of coated oral dosage forms. International Journal of Pharmaceutics. 2024;666:124841. https://doi.org/10.1016/j.ijpharm.2024.124841
- ICH. Q8(R2) Pharmaceutical Development. August 2009. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
- EMA. Guideline on real-time release testing (formerly guideline on parametric release). Revision 1. EMA/CHMP/QWP/811210/2009-Rev1. 2012. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-real-time-release-testing-formerly-guideline-parametric-release-revision-1_en.pdf
Evidence note: Manufacturer descriptions establish stated product capabilities; research publications support the technical discussion. The financial scenario and proposed operational benefits are analytical illustrations, not reported OSeeT commercial performance data











































All4Nutra







